JPH03161448A - Composition containing oil and fat - Google Patents
Composition containing oil and fatInfo
- Publication number
- JPH03161448A JPH03161448A JP29951289A JP29951289A JPH03161448A JP H03161448 A JPH03161448 A JP H03161448A JP 29951289 A JP29951289 A JP 29951289A JP 29951289 A JP29951289 A JP 29951289A JP H03161448 A JPH03161448 A JP H03161448A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- fat
- weight
- parts
- fats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000003921 oil Substances 0.000 claims abstract description 180
- 229920005862 polyol Polymers 0.000 claims abstract description 26
- 150000003077 polyols Chemical class 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 239000003925 fat Substances 0.000 claims description 131
- 235000019198 oils Nutrition 0.000 abstract description 175
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 61
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 25
- 239000007788 liquid Substances 0.000 abstract description 20
- 239000011230 binding agent Substances 0.000 abstract description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract description 7
- 229920002472 Starch Polymers 0.000 abstract description 6
- 239000008107 starch Substances 0.000 abstract description 6
- 235000019698 starch Nutrition 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 150000004676 glycans Chemical class 0.000 abstract description 2
- 229920001282 polysaccharide Polymers 0.000 abstract description 2
- 239000005017 polysaccharide Substances 0.000 abstract description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 239000008158 vegetable oil Substances 0.000 abstract description 2
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 128
- 239000000843 powder Substances 0.000 description 49
- 235000011187 glycerol Nutrition 0.000 description 29
- 238000000034 method Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 22
- 239000008187 granular material Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 238000002386 leaching Methods 0.000 description 14
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 11
- 235000011613 Pinus brutia Nutrition 0.000 description 11
- 241000018646 Pinus brutia Species 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 235000014593 oils and fats Nutrition 0.000 description 11
- 235000012424 soybean oil Nutrition 0.000 description 11
- 239000003549 soybean oil Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 8
- 238000005470 impregnation Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- -1 that is Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 235000019625 fat content Nutrition 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000011164 primary particle Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000002316 solid fats Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ULLNJSBQMBKOJH-VIVFLBMVSA-N (3R,4R,5R)-5-[(1R)-1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxy-3-oxolanol Chemical compound C([C@H]([C@H]1OC([C@@H]([C@H]1OCC=1C=CC=CC=1)O)OCC)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 ULLNJSBQMBKOJH-VIVFLBMVSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 2
- 229920001386 Gefarnate Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960003779 gefarnate Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940033331 soy sterol Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960003567 tribenoside Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BAMZQDVORMCDEA-UHFFFAOYSA-N 5-oxoicosanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)CCCC(O)=O BAMZQDVORMCDEA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- BBRBUTFBTUFFBU-LHACABTQSA-N Ornoprostil Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(=O)OC BBRBUTFBTUFFBU-LHACABTQSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229950009738 ornoprostil Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- SUWYPNNPLSRNPS-UNTSEYQFSA-N plaunotol Chemical compound CC(C)=CCC\C(C)=C\CC\C(CO)=C\CC\C(C)=C\CO SUWYPNNPLSRNPS-UNTSEYQFSA-N 0.000 description 1
- 229950009291 plaunotol Drugs 0.000 description 1
- SUWYPNNPLSRNPS-UHFFFAOYSA-N plaunotol Natural products CC(C)=CCCC(C)=CCCC(CO)=CCCC(C)=CCO SUWYPNNPLSRNPS-UHFFFAOYSA-N 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、医薬分野において、油脂、油脂包含用基剤、
ボリオールと、さらに油脂吸収基剤、結合剤からなる薬
効成分を有する油脂含有組成物に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention is applicable to the pharmaceutical field, which includes oils and fats, bases for containing oils and fats,
The present invention relates to a fat-and-oil-containing composition having a medicinal ingredient consisting of polyol, a fat-absorbing base, and a binder.
(従来の技術)
浦性物質は一般に取り扱いが困難なため、物性の改善が
必要とされる。中でも、医薬品として使用される油性物
質、すなわち、油性薬物については、物性の改善のみで
なく、消化管における吸収性も考慮した改良が必要とな
る。そこで、これらの要求を満たす油性薬物製剤として
、水中分散機能をもつ粉末製剤が必要とされる。(Prior Art) Since porcelain materials are generally difficult to handle, it is necessary to improve their physical properties. Among these, oil-based substances used as pharmaceuticals, that is, oil-based drugs, require improvements that take into account not only the physical properties but also the absorbability in the gastrointestinal tract. Therefore, as an oil-based drug formulation that satisfies these requirements, a powder formulation with water dispersibility is required.
従来、油脂の粉末化の製造方法としては、■高融点の固
形脂を低温で粉砕して粉末化する凍結粉砕法。■加工澱
粉、セルロース等の含油性基剤に油脂を含浸させる含浸
法。■シュガーエステル等の合或乳化剤、カゼインやゼ
ラチン等の蛋白質あるいは澱粉等を用いて水中油型乳化
物を作り、これを噴霧乾燥するスプレードライ法(特開
昭55−150845)がある。Conventionally, methods for producing powdered oils and fats include: (1) Freeze-grinding method, in which solid fats with a high melting point are pulverized at low temperatures and pulverized. ■An impregnation method in which oil-impregnated base materials such as modified starch and cellulose are impregnated with fats and oils. (2) There is a spray drying method (Japanese Unexamined Patent Publication No. 150845/1984) in which an oil-in-water emulsion is prepared using a co-emulsifier such as sugar ester, a protein such as casein or gelatin, or starch, and this is spray-dried.
■の凍結粉砕法は、融点60’C以上の極度硬化油にし
か適用できないため、得られる粉末油脂は溶けが非常に
遅く、溶解ばらつきが大きいことから、通常医薬の使用
には適さない。The freeze-grinding method (2) can only be applied to extremely hardened oils with a melting point of 60'C or higher, and the resulting powdered oils and fats melt very slowly and have large variations in solubility, making them generally unsuitable for pharmaceutical use.
また、■の含浸法は、従来より製剤技術として確立され
た方法であり、商品化もなされているが、その方法によ
って得られる粉末油脂は、油脂の浸み出し、粉体の流動
性低下等の問題から低油脂含量に限られるため、高含量
の油脂を含有させたい場合には適した技術ではない。In addition, the impregnation method (2) is a method that has been established as a formulation technology and has been commercialized, but the powdered fats and oils obtained by this method have problems such as oozing of fats and oils and a decrease in the fluidity of the powder. Because of this problem, it is limited to low oil and fat contents, so it is not a suitable technique when it is desired to contain a high oil and fat content.
また、■のスプレードライ法は、乳化度が高い粘性を示
すため、水分を70〜90%程度まで高めないと噴霧乾
燥できず、蒸発させるべき水の量が多大であり、したが
って、エネルギーコストが膨大になる。In addition, in the spray drying method (2), since the degree of emulsification is high and the viscosity is high, spray drying cannot be performed unless the water content is increased to about 70 to 90%, and the amount of water that must be evaporated is large, resulting in low energy costs. It becomes huge.
一方、油脂を含有する食用組或物への液体ボリオールの
応用化技術として、特開昭64−27430がある。こ
れはポリオールを含有する粉状または粒状油脂およびそ
の製造方法に関するものであり、粉末油脂からの油脂の
浸み出しを改良した技術であるが、油脂の僅かの浸み出
しが避けられないことから、医薬の分野においての適応
は難しい技術である。On the other hand, Japanese Patent Application Laid-Open No. 64-27430 is a technology for applying liquid polyols to edible compositions containing fats and oils. This relates to powdered or granular fats and oils containing polyols and their manufacturing method, and is a technology that improves the leaching of fats and oils from powdered fats, but since a slight leaching of fats and oils is unavoidable, , is a difficult technology to apply in the pharmaceutical field.
従来の液状油性薬物の充填は、薬物を軟カプセルに充填
するか、粉末からにじみ出さない程度の極少量の液状油
性薬物を含浸基剤に含浸させる方法がとられており、高
含量の液状油性薬物からなり、しかも、固く流動性の良
い粉末油脂を得る技術はないのが現状である。Conventional methods for filling liquid oil-based drugs include filling soft capsules with the drug, or impregnating an impregnation base with a very small amount of liquid oil-based drug that does not ooze out of the powder. At present, there is no technology for obtaining powdered oils and fats made of drugs that are hard and have good fluidity.
(発明が解決しようとする課題)
油脂を粉末化する製剤技術としては、粉末からにじみ出
さない程度の極少量の液状油性薬物を含油性基剤に含浸
させる方法がとられている。この含浸法によって得られ
る粉末油脂は、油脂の浸み出し、粉体の流動性低下等の
問題から低油脂含量になってしまうため、含浸法では目
的とする高含量粉末油脂は得ることができない。さらに
、得られる粉末は、含油性基剤の比容積が大きい等の物
性に起因して柔らかくなるために、流動性が悪くなると
いう欠点を有している。(Problems to be Solved by the Invention) As a formulation technology for powdering fats and oils, a method has been adopted in which an oil-impregnated base is impregnated with a very small amount of liquid oil-based drug that does not ooze out from the powder. Powdered fats and oils obtained by this impregnation method have low fats and oils content due to problems such as leaching of fats and oils and decreased fluidity of the powder, so it is not possible to obtain the desired powdered fats and oils with a high content using the impregnation method. . Furthermore, the resulting powder becomes soft due to physical properties such as a large specific volume of the oil-containing base, and has the disadvantage of poor fluidity.
また、前述の特開昭64−27430に記載の油脂を含
有する食用組或物への液体ポリオールの応用化技術は、
液体ポリオールを添加することで油脂の浸み出しの少な
い流動性の良い粉粒体を得るための技術であるが、粉末
油脂から゛の油脂の僅かの浸み出しが避けられない。医
薬品において油脂の浸み出しがあることは、■製剤中の
生薬である油性薬物の含量低下を示唆することであり、
患者に所定量の薬物を投与できなくなってしまう。In addition, the application technology of liquid polyol to edible compositions containing fats and oils described in the above-mentioned Japanese Patent Application Laid-open No. 64-27430 is as follows:
Although this is a technique for obtaining powder and granules with good fluidity and less oozing of oil and fat by adding a liquid polyol, a slight amount of leaching of the oil and fat from the powdered oil and fat is unavoidable. The oozing of oils and fats in pharmaceuticals suggests a decrease in the content of oil-based drugs, which are crude drugs, in the preparation.
It becomes impossible to administer the prescribed amount of drug to the patient.
■食品の場合、多少包装材料に油脂が付着しても、人体
への影響度は少なくてすむが、医薬品の場合、包装材料
への付着は、■の含量低下の問題点があるうえに、患者
が服用する際に不便である。以上の点より僅かでも油脂
の浸み出しがあることは、医薬の分野において適応は非
常に難しくなる。したがって、高含量の油脂でも、油脂
の浸み出しのない、かつ、粉末として十分な強度を有す
る製剤製造技術の確立が必要とされている。■In the case of food products, even if some amount of oil or fat adheres to the packaging material, the impact on the human body is minimal, but in the case of pharmaceuticals, adhesion to the packaging material has the problem of reducing the content of ■. It is inconvenient for patients to take. From the above points, even the slightest leaching of fats and oils makes it extremely difficult to apply in the pharmaceutical field. Therefore, there is a need to establish a technology for producing a formulation that does not seep out even with a high content of fat and oil and has sufficient strength as a powder.
(課題を解決するための手段)
本発明者らは、油の浸み出し等の従来技術の持つ問題点
を克服するため鋭意研究の結果、油脂、油脂吸収基剤、
結合剤および油脂包含用基剤、ボリオールとを含んでな
る油脂含有組或物とすることにより、高含量の油脂を含
有し、さらに、油の浸み出しがなく、製剤工程中におい
ても十分な強度を有する粉状または粒状油脂を完成する
に至った。(Means for Solving the Problems) As a result of intensive research to overcome the problems of conventional techniques such as oil seepage, the present inventors have discovered that oils and fats, oil and fat absorption bases,
By creating an oil-containing composition comprising a binder, a base for containing oils and fats, and a polyol, it contains a high content of oils and fats, and furthermore, there is no leaching of oil and a sufficient amount of oil can be maintained even during the formulation process. We have completed a powdered or granular oil with strength.
本発明の粉状または粒状油脂の好ましい組或は、油脂1
〜70重量%、さらに好ましくは60重景%までの油脂
、油脂吸収基剤1〜20重量%、さらに好ましくは5〜
15重量%、結合剤0.1〜15重量%、さらに好まし
くは1〜5重量%、油脂包含用基剤30〜90重量%、
さらに好ましくは50〜80重量%、ポリオール0.
1〜10重量%、さらに好ましくは2〜5重量%であ
る。Preferred composition of powdery or granular fats and oils of the present invention or fats and oils 1
-70% by weight, more preferably up to 60% by weight of fats and oils, 1-20% by weight of fat-absorbing base, more preferably 5-20% by weight
15% by weight, binder 0.1 to 15% by weight, more preferably 1 to 5% by weight, base for fat and oil inclusion 30 to 90% by weight,
More preferably 50 to 80% by weight and 0.0% by weight of polyol.
It is 1 to 10% by weight, more preferably 2 to 5% by weight.
上記組或の粉末化または顆粒化したものは、特に油脂の
浸み出しがなく、製剤工程に耐え得る強度を有しており
、しかも、流動性は良好であることから、医薬品として
の使用に問題はない。Powdered or granulated products of the above composition are particularly suitable for use as pharmaceuticals because they do not seep out of oil and fat, have strength that can withstand the formulation process, and have good fluidity. No problem.
本発明で言う油脂包含用基剤とは、油脂を包蔵または含
浸させるための基剤を言う。The base for containing fats and oils in the present invention refers to a base for encapsulating or impregnating fats and oils.
本発明で用いる油脂包含用基剤としては、親水性、疎水
性どちらの物質でもよく、具体的には、デキストリン(
例えば、パインデックス[F]#1゛等の澱粉部分加水
分解物、ゼラチン、カゼイン、アルブミン等の親水性タ
ンパク質、澱粉、カルボキシメチルセルロース等の親水
性多糖類、グルタミン酸、リジンに代表される親水性ア
ミノ酸またはその塩、乳糖に代表される[M、クエン酸
、コハク酸、アジピン酸等の有機酸またはその塩、およ
び塩化ナトリウム、塩化カリウム等の通常医薬品に使用
される塩類のいずれか、またはこれら2種以上の混合物
、あるいは少なくともこれらのいずれかを含有する医薬
品組或物を挙げられるが、中でも分解率の低い澱粉部分
加水分解物であるデキストリンが好ましい。The base for inclusion of fats and oils used in the present invention may be either hydrophilic or hydrophobic substances, and specifically, dextrin (
For example, starch partial hydrolysates such as Pinedex [F] #1, hydrophilic proteins such as gelatin, casein, and albumin, starch, hydrophilic polysaccharides such as carboxymethyl cellulose, and hydrophilic amino acids such as glutamic acid and lysine. or its salts, organic acids such as lactose [M, citric acid, succinic acid, adipic acid, etc., or their salts, and salts commonly used in pharmaceuticals such as sodium chloride, potassium chloride, etc., or any of these two. Examples include a mixture of more than one species, or a pharmaceutical composition containing at least one of them, but among them, dextrin, which is a starch partial hydrolyzate with a low decomposition rate, is preferred.
本発明で用いる油脂包含用基剤の形状は特に限定されな
いが、粉粒状(球形)が好ましく、その好ましい粒径は
50メッシュバス(Mesh pass)以下、さらに
好ましくは100メノシュパス(Meshpass)以
下である。また、該基剤は、レシチン等の乳化性基剤を
含有しない方が好ましい。The shape of the fat/oil inclusion base used in the present invention is not particularly limited, but it is preferably powder-like (spherical), and its preferred particle size is 50 mesh passes or less, more preferably 100 mesh passes or less. . Further, it is preferable that the base does not contain an emulsifying base such as lecithin.
本発明で言う油脂とは、植物油、医薬合或油、または固
形脂、半固形脂、液状油およびこれら2種以上の混合吻
のいずれでもよく、特に限定されない。例えば、ビタξ
ンA、ビタミンEなどの脂溶性ビタミンおよびその誘導
体、リノール酸、リノレン酸、アラキドン酸、EPA、
ドコサヘキサエン酸などの脂質類、ニフェジビン、ゲフ
ァルナート、プラウノトール、クロフィブラート、トリ
ベノシド等の天然または合戒による医薬品、さらにはオ
ルノプロスチル等のプロスタグランジン系の薬物、ソイ
ステロール等の植物ステロールが挙げられる。The fats and oils referred to in the present invention are not particularly limited and may be vegetable oils, pharmaceutical oils, solid fats, semi-solid fats, liquid oils, or mixtures of two or more of these. For example, bita ξ
Fat-soluble vitamins and their derivatives such as vitamin A and vitamin E, linoleic acid, linolenic acid, arachidonic acid, EPA,
Examples include lipids such as docosahexaenoic acid, natural or prescribed medicines such as nifedibine, gefarnate, plaunotol, clofibrate, tribenoside, prostaglandin drugs such as ornoprostil, and plant sterols such as soysterol.
本発明で用いる油脂吸収基剤としては、含油性能の高い
ものが望ましく、例えば、メタケイ酸アル旦ン酸マグネ
シウム、ケイ酸マグネシウム、酸化マグネシウム、乾燥
水酸化アルミニウムゲル、合成ケイ酸アルミニウムなど
のアルミニウム化合物、マグネシウム化合物、アビセル
等のセルロース類軽質無水ケイ酸等が挙げられるが、中
でも軽質無水ケイ酸が好ましい。The oil-absorbing base used in the present invention is preferably one with high oil-retaining properties, such as aluminum compounds such as magnesium metasilicate aldanate, magnesium silicate, magnesium oxide, dry aluminum hydroxide gel, and synthetic aluminum silicate. , magnesium compounds, celluloses such as Avicel, and light silicic anhydride, among which light silicic anhydride is preferred.
本発明で用いるポリオールとしては、グリセリン、プロ
ピレングリコール等の無毒性グリコール、および糖類ま
たは糖アルコール類が挙げられるが、中でも常温で液体
のポリオールが好ましく、さらに好ましくはグリセリン
である。Examples of the polyol used in the present invention include non-toxic glycols such as glycerin and propylene glycol, and sugars or sugar alcohols. Among them, polyols that are liquid at room temperature are preferred, and glycerin is more preferred.
また、本発明で使用する結合剤は、医薬的に許容される
結合剤であればよく、具体的には、アラビアゴム、トラ
ガント、ゼラチン、デンプン、メチルセルロース、カル
ボキシメチルセルロースーNa,HPMC、ポリビニル
ピロリドンが挙げられるが、中でもポリビニルビロリド
ンが好ましい。Further, the binder used in the present invention may be any pharmaceutically acceptable binder, and specifically, gum arabic, tragacanth, gelatin, starch, methylcellulose, carboxymethylcellulose-Na, HPMC, and polyvinylpyrrolidone are used. Among these, polyvinylpyrrolidone is preferred.
次に、本発明の粉末化または粒状油脂を製造する方法に
ついて説明する。Next, a method for producing powdered or granular fats and oils of the present invention will be explained.
本発明の粉状または粒状油脂は、1〜70重量%の油脂
、1〜20重量%の油脂吸収基剤、0.l〜15重量%
の結合剤、30〜90重量%の油脂包含用基剤、および
1〜10重量%のボリオールを、該油脂の融点以上の温
度において均一に混合攪拌することによって得られる。The powdered or granular fat or oil of the present invention comprises 1 to 70% by weight of fat, 1 to 20% by weight of fat-absorbing base, and 0.5% by weight of fat-and-oil absorption base. l~15% by weight
It is obtained by uniformly mixing and stirring a binder, 30 to 90% by weight of a base for inclusion of fat and oil, and 1 to 10% by weight of polyol at a temperature equal to or higher than the melting point of the fat or oil.
上記原料の混合方法は特に限定されないが、油脂、油脂
吸収基剤、結合剤および油脂包含用基剤を均一に7昆合
した後、ポリオールを均一に混合する方法が好ましい。Although the method for mixing the above-mentioned raw materials is not particularly limited, it is preferable to uniformly combine the fats and oils, the fat-and-oil absorption base, the binder, and the base for including fats and oils, and then uniformly mix the polyol.
これら混合物は造粒工程を経て、さらに、60゜C付近
で5分間加熱することにより、固く流動性の良い油脂含
有組成物が得られる。本発明において、上記混合時点に
おけるポリオールの性状は液状とする。すなわち、グリ
セリン、プロピレングリコール等のグリコール類は、そ
の融点以上の温度に保ち、媚類または糖アルコール類の
場合は、できる限り高濃度の水溶液とする。These mixtures are subjected to a granulation process and further heated at around 60°C for 5 minutes to obtain a hard oil-containing composition with good fluidity. In the present invention, the polyol is in a liquid state at the time of mixing. That is, glycols such as glycerin and propylene glycol are kept at a temperature above their melting point, and in the case of aphrodisiacs or sugar alcohols, they are made into an aqueous solution with the highest possible concentration.
油脂、油脂吸収基剤、油脂包含用基剤、結合剤およびポ
リオールを含んでなる原料組或物の混合時点における好
ましい水分含量は15重量%以下、さらに好ましくは1
0重量%以下である。この理由は、油脂含有組或物のポ
リオールによる粉粒化現象が、水分の多い系では進行し
ないからである。The preferred water content at the time of mixing of the raw material composition comprising fats and oils, a fat-absorbing base, a base for containing fats and oils, a binder and a polyol is 15% by weight or less, more preferably 1% by weight or less.
It is 0% by weight or less. The reason for this is that the pulverization phenomenon of the oil- and fat-containing composition due to the polyol does not proceed in a system with a high moisture content.
ただし、原料組威物を水に分散させて噴霧乾燥し、粉粒
化することも可能である。However, it is also possible to disperse the raw materials in water, spray dry them, and pulverize them.
さらに、常温で油脂に溶解または分散懸濁化させた薬物
を粉粒化することも可能である。Furthermore, it is also possible to pulverize a drug dissolved or dispersed in oil or fat at room temperature.
本発明において、油脂、油脂吸収基剤、油脂包含用基剤
、結合剤および液状のポリオールの混合魔拌に用いる機
器は、通常の医薬製造工程上用いる混合機、混練機、造
粒機等が使用でき、特に限定されない。混合時間はスケ
ールや使用する原料などにより異なるので、適宜設定し
て行う。In the present invention, the equipment used to mix and stir the fats and oils, fat-absorbing base, base for containing fats and oils, binder, and liquid polyol is a mixer, a kneader, a granulator, etc. used in normal pharmaceutical manufacturing processes. It can be used without any particular limitation. The mixing time varies depending on the scale and the raw materials used, so it is set appropriately.
本発明の粉状または粒状油脂の製造において、高速撹拌
造粒機、撹拌翼付流動層造粒機等を用いれば、200〜
1000μmの比較的粒度のそろった籾状または粒状油
脂が得られるが、用いる機器または用途によっては、粉
粒化後、整粒することによって、希望する粒度範囲のも
ののみを用いることも可能である。In the production of powdery or granular fats and oils of the present invention, if a high-speed stirring granulator, a fluidized bed granulator with stirring blades, etc. are used,
Rice-like or granular fats and oils with a relatively uniform particle size of 1000 μm can be obtained, but depending on the equipment or purpose used, it is possible to use only those in the desired particle size range by sizing after pulverization. .
本発明の粉状または粒状油脂の製造上重要なことは、1
〜70重量%の油脂に対して1〜20重量%の油脂吸収
基剤と0. 1〜15重量%の結合剤を共に加えるこ
とである。本発明では、高含量の油脂からなる流動性の
良い粉体を得ること、さらに、油脂の浸み出しがないこ
とを目的としているが、油脂包含用基剤のみでは流動性
の良い粉体は得られても、油脂の浸み出しがあるため目
的は達しえない。しかし、油脂吸収基剤と結合剤を加え
ることにより、含油性能の高い油脂吸収基剤が油脂をと
らえ油脂含有組成物の核となり、さらに、結合剤が核を
固くするため、油脂包含用基剤が核を覆い易くなると考
えられる。そのため目的とする油脂の浸み出しのない、
流動性の良い粉体を得ることが可能になると思われる。The important points in producing the powdered or granular fats and oils of the present invention are 1.
~70% by weight of oil, 1 to 20% by weight of fat-absorbing base and 0. 1 to 15% by weight of binder is added together. The purpose of the present invention is to obtain a powder with good fluidity consisting of a high content of fats and oils, and also to avoid oozing of fats and oils. Even if it is obtained, the purpose cannot be achieved due to leaching of oil and fat. However, by adding an oil- or fat-absorbing base and a binder, the oil- or fat-absorbing base with high oil-retaining performance captures the oil and becomes the core of the oil-containing composition, and the binder hardens the core. It is thought that this makes it easier to cover the nucleus. Therefore, the target oil and fat will not seep out.
It seems possible to obtain a powder with good fluidity.
この範囲外の油脂吸収基剤量では、比容積が大きい物性
上造粒物の流動性が悪くなり、さらに、油脂の浸み出し
があるため目的は達せられない。さらに、本発明におい
て重要なことは、0.1〜10重量%の液体ボリオール
を他の原料組威中に均一に分散させることである。ポリ
オールを均一に分敗させ、さらに、造粒工程後、60’
C付近で5分間加熱することで、目的とする固い油脂含
有組成物が得られる。If the amount of the fat-absorbing base is outside this range, the fluidity of the granulated product will be poor due to its large specific volume, and furthermore, the fats and oils will seep out, so that the objective cannot be achieved. Furthermore, what is important in the present invention is to uniformly disperse 0.1 to 10% by weight of the liquid polyol into the other raw materials. The polyol is uniformly separated, and after the granulation process, 60'
By heating around C for 5 minutes, the desired hard oil-containing composition can be obtained.
特にグリセリンや高濃度の糖アルコール水溶液のような
高粘度の液体を分散させる場合、加温して噴霧するのが
極めて効果的である。In particular, when dispersing a highly viscous liquid such as glycerin or a highly concentrated sugar alcohol aqueous solution, heating and spraying is extremely effective.
上記の製造方法によって簡単に油脂を粉末化できる理由
、および本発明の粉状または粒状油脂が加水時に速やか
に油脂を分離する理由は、必ずしも明確ではないが、以
下のように推察される。The reason why fats and oils can be easily powdered by the above production method and the reason why the powdered or granular fats and oils of the present invention quickly separates fats and oils when water is added are not necessarily clear, but are speculated as follows.
すなわら、油脂、油脂吸収基剤、結合剤を混合すること
により、固く油脂を含有した核が形威される。さらに、
この核の周囲を油脂包含用基剤が覆い、液状のポリオー
ルで均一に混合攪拌することによって、ポリオールが親
水性の油脂包含用基剤の一次粒子間を架橋し造粒(3次
元の構造体を形成)しながら、その一次粒子間の空隙に
油脂を包接するものと考えられる。したがって、加水時
には、親水性の油脂包含用基剤とボリオールからなる親
水性の構造体が溶解し、内部の油脂が放出されるものと
推測される。That is, by mixing the oil, fat-absorbing base, and binder, a solid core containing oil and fat is formed. moreover,
The core is covered with a base for containing fats and oils, and by uniformly mixing and stirring with liquid polyol, the polyol crosslinks between the primary particles of the hydrophilic base for containing fats and oils, resulting in granulation (three-dimensional structure). It is thought that oils and fats are included in the voids between the primary particles while forming (forming) the primary particles. Therefore, it is presumed that when water is added, the hydrophilic structure consisting of the hydrophilic base for containing fats and oils and the polyol dissolves, and the fats and oils inside are released.
(発明の効果)
本発明の油脂含有Mi戒物は、以下に示すような優れた
特徴を有する。(Effects of the Invention) The oil-containing Mi prefecture of the present invention has the following excellent characteristics.
1)通常の含浸法によって得られる粉末油脂に比べ、油
脂の浸み出しが極めて少ない。特に油脂含量が30%以
上、さらには50%以上という高油脂含量でも油脂の浸
み出しがない。したがって、粉体の流動性が非常に良い
。1) Compared to powdered fats and oils obtained by normal impregnation methods, leaching of fats and oils is extremely small. In particular, there is no leaching of fats and oils even at high fat and oil contents of 30% or more, and even 50% or more. Therefore, the powder has very good fluidity.
2)70重量%までの高含量油脂からなる粉粒体製造が
可能である。2) It is possible to produce granules containing high oil and fat content up to 70% by weight.
3)液体ポリオール添加により、固く、しがも、加水時
の油脂の分離が速やかに起こり、分散性が良い粉体が得
られる。3) By adding a liquid polyol, a hard powder with good dispersibility can be obtained, with quick separation of fats and oils when water is added.
4)液体ポリオールによる油脂包接効果により、臭いや
不快な呈味感を避けることができる。4) Odor and unpleasant taste can be avoided due to the fat and oil inclusion effect of the liquid polyol.
5)乾燥工程を必要とせず、製造方法が極めて簡便で経
済的である。5) No drying process is required, and the manufacturing method is extremely simple and economical.
6)液状油性薬物、固形脂等、いかなる油脂にも適用で
き、得られる粉末油脂の用途が広い。6) It can be applied to any oil such as liquid oil-based drugs and solid fat, and the resulting powdered oil has a wide range of uses.
7)油脂を共存させることにより、消化管吸収が促進さ
れる薬物を油脂に分散懸濁化させた後、粉末化製剤にす
ることも可能である。7) Gastrointestinal absorption is promoted by the coexistence of fats and oils After dispersing and suspending the drug in fats and oils, it is also possible to make a powdered preparation.
8)水と接触することで分解しゃすい薬物を油脂に分散
懸濁化させた後、粉末化製剤とし安定化をはかることも
可能である。8) It is also possible to disperse and suspend a drug that easily decomposes on contact with water in oil and fat, and then stabilize it as a powdered preparation.
以下の実験例により、本発明の効果をさらに詳細に示す
。処方1〜処方7まで検討に使用した試料のそれぞれの
処方を示す。処方1〜処方6は油脂含量35重量%、処
方7は油脂含量60重量%であり、処方6および7が本
発明の組威物である。The following experimental examples demonstrate the effects of the present invention in more detail. Prescriptions 1 to 7 show the respective prescriptions of the samples used in the study. Formulation 1 to Formulation 6 have an oil content of 35% by weight, Formulation 7 has an oil content of 60% by weight, and Formulation 6 and 7 are the compositions of the present invention.
製造方法
以下各処方例で示した基剤を均一に混合撹拌後、造粒工
程を経て60゜C付近で5分間加熱することにより粉粒
体を得た。Manufacturing method: After uniformly mixing and stirring the bases shown in each formulation example below, a powder was obtained by heating at around 60°C for 5 minutes through a granulation process.
〈実験例〉
処方1
軽質無水ケイ酸 65重量部大豆油
35重量部処方2
軽質無水ケイ酸 63重量部ポリビニル
ピロリドン(K−90) 2重量部大豆油
35重量部処方3
パインデンクス[F]# 1 (DE・8) 65重
量部大豆油 35重量部グリセ
リン 3重量部処方4
パインデンクス■# 1 (DE・8)ポリビニルピロ
リドン(K−90)
大豆油
グリセリン
処方5
パインデックス[F]# 1 (DE=8)軽質無水ケ
イ酸
ポリビニルピロリドン(K−90)
大豆油
処方6
パインデックス■# 1 (DE・8)軽質無水ケイ酸
ポリビニルピロリドン(K−90)
大豆油
グリセリン
処方7
パインデックス■# 1 (DE・8)軽質無水ケイ酸
ポリビニルピロリドン(K−90)
大豆油
65重量部
2重量部
35重量部
3重量部
53重量部
10重量部
2重量部
35重量部
53重量部
10重量部
2重量部
35重量部
3重量部
33重量部
30重量部
2重量部
99重量部
グリセリン 3重量部表lに各処
方における油脂の浸み出し、安息角および固さの測定結
果を示した。各評価方法について以下に記載する。<Experimental example> Formulation 1 Light anhydrous silicic acid 65 parts by weight Soybean oil
35 parts by weight Formula 2 Light silicic anhydride 63 parts by weight Polyvinylpyrrolidone (K-90) 2 parts by weight Soybean oil
35 parts by weight Formulation 3 Pine Denks [F] #1 (DE・8) 65 parts by weight Soybean oil 35 parts by weight Glycerin 3 parts by weight Formulation 4 Pine Denks #1 (DE・8) Polyvinylpyrrolidone (K-90) Soybean oil glycerin prescription 5 Pine Index [F] # 1 (DE=8) Light anhydrous polyvinyl pyrrolidone silicate (K-90) Soybean oil formulation 6 Pine Index # 1 (DE/8) Light polyvinyl pyrrolidone silicate anhydride (K-90) Large Soybean oil glycerin formulation 7 Pine Index #1 (DE・8) Light anhydrous polyvinylpyrrolidone silicate (K-90) Soybean oil 65 parts by weight 2 parts by weight 35 parts by weight 53 parts by weight 10 parts by weight 2 parts by weight 35 parts by weight Part 53 parts by weight 10 parts by weight 2 parts by weight 35 parts by weight 3 parts by weight 33 parts by weight 30 parts by weight 2 parts by weight 99 parts by weight Glycerin 3 parts by weight The measurement results are shown. Each evaluation method is described below.
評価法
■ 油脂の浸み出しは、ろ紙上に28メッシュのふるい
を通過した32メッシュ上の試料約1gをのせ、さらに
、その上にろ紙をかぶせ、重りとして200gをのせる
。3時間後の残存率を求め、浸み出しのないことを0%
として油脂の浸み出しを計算する。Evaluation method ■ To measure the leaching of fats and oils, place approximately 1 g of a 32-mesh sample that has passed through a 28-mesh sieve on a filter paper, then cover the filter paper and place 200 g as a weight. Determine the residual rate after 3 hours, and 0% indicates no seepage.
Calculate the oil seepage as .
■ 安息角は、残留円錘法に基づくパウダーデスクー〔
商品名;小西FK型安息角測定器]によって測定する。■ The angle of repose is determined by powder desk calculation based on the residual cone method.
Product name: Konishi FK type angle of repose measuring device].
測定試料の粒度は28メッシュのふるいを通過した32
メッシュ上の試料15gを使用する。The particle size of the measurement sample was 32 after passing through a 28 mesh sieve.
Use 15 g of sample on the mesh.
■ 粉粒体の固さについては、油脂の浸み出し試験終了
後、試料を32メッシュのふるいにかけた後のふるい上
の残存率で測定する。■ The hardness of the powder is measured by the percentage remaining on the sieve after passing the sample through a 32-mesh sieve after the oil and fat leaching test.
表1
油脂の浸み出し、
安息角および固さ測定
表1の結果から、本発明の処方である6および7は、油
脂の浸み出しがほとんどない。安息角も粉体としては良
好な数値を示している。粒状油脂の固さについては、処
方3および4よりやや劣るものの、従来の含浸法(処方
l)に比較すると、固さは格段に向上したと考えられる
。処方7の結果から、油脂含量60重量%の粒状油脂が
良好に製造できることがわかった。したがって、本発明
の粉末は、油脂の浸み出しがなく、粉粒体としての流動
性も良好なことが観察された。Table 1 Leaching of fats and oils, angle of repose and hardness measurement From the results in Table 1, formulations 6 and 7 of the present invention have almost no leaching of fats and oils. The angle of repose also shows good values for a powder. Although the hardness of the granular oil and fat is slightly inferior to Formulas 3 and 4, it is considered that the hardness is significantly improved compared to the conventional impregnation method (Formulation 1). From the results of Formulation 7, it was found that granular fats and oils with a fat content of 60% by weight could be produced satisfactorily. Therefore, it was observed that the powder of the present invention did not seep out of oil and fat and had good fluidity as a powder or granule.
以上をまとめると、本発明によって得られる粒状油脂は
、水によって崩壊しゃすい組戒および構造を形威してい
るため、加水時の油脂の分離が速やかに起こることから
、速い放出が望まれる環境下において良好な放出(速放
性)が期待される。To summarize the above, the granular fats and oils obtained by the present invention have a composition and structure that easily disintegrates with water, so separation of the fats and oils occurs quickly when water is added, and therefore, environments where rapid release is desired. Good release (immediate release) is expected at lower temperatures.
また、通常の含浸法によって得られる粉末油脂に比べ、
油脂含量が高い上に、油脂の浸み出しもなく、固い粉粒
体が得られることから流動性が高い。しかも、液状油、
固形脂等、いかなる油脂にも適用でき、用途が広い利点
を有している。油脂含量が高いことは、医薬品の投与量
の減少、すなわち、カプセル等の小型化の応用も期待で
きる。In addition, compared to powdered fats and oils obtained by normal impregnation methods,
It has a high oil and fat content, and has high fluidity because it produces hard powder and granules without leaching of oil and fat. Moreover, liquid oil
It can be applied to any type of fat or oil, including solid fats, and has the advantage of being versatile. The high oil and fat content can be expected to be applied to reduce the dosage of pharmaceuticals, that is, to miniaturize capsules and the like.
さらに、液状油性薬物を粉末化することにより、薬物の
充填および操作性は極めて向上し、病院内での調剤、さ
らに、患者への投与時煩雑さが少なくなり、操作がより
簡便になる。Furthermore, by pulverizing a liquid oil-based drug, the ease of filling and handling the drug is greatly improved, making dispensing within a hospital and administering it to a patient less complicated and easier to operate.
また、粉末油脂は、液状油性薬物の粉末化の他に、錠剤
、カプセル剤等の固形製剤の中間原料としての用途が考
えられる。In addition to powdering liquid oil-based drugs, powdered oils and fats can be used as intermediate raw materials for solid preparations such as tablets and capsules.
(実施例)
以下に本発明の実施例を示すが、本発明は、これらの実
施例により限定されるものではない。(Examples) Examples of the present invention are shown below, but the present invention is not limited to these Examples.
実施例1
ビタごンE 35重量部軽質無水ケ
イ酸 10重量部ポリビニルピロリドン(
K−90) 2重量部パインデックス[F]#1
53重量部グリセリン 3重
量部製造方法
35重量部のビタミン巳と10重量部の軽質無水ケイ酸
と2重量部のポリビニルビロリドン(K〜90)および
53重量部のバインデックス[F]#lを十分に混練後
、さらに、3重量部のグリセリンを添加し、均一になる
ように攪拌を行い造粒工程後、60゜C5分間加熱する
ことにより粉粒体を得た。Example 1 Vitagon E 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (
K-90) 2 parts by weight Pine Index [F] #1
53 parts by weight Glycerin 3 parts by weight Production method 35 parts by weight of Vitamin C, 10 parts by weight of light silicic acid anhydride, 2 parts by weight of polyvinylpyrrolidone (K~90) and 53 parts by weight of binder index [F] #l After sufficiently kneading, 3 parts by weight of glycerin was further added and stirred to make the mixture uniform. After the granulation process, the mixture was heated at 60° C. for 5 minutes to obtain powder.
得られた粉粒体の安息角は44゜で、油脂の浸み出しは
全くなく、粉粒体の固さも91。7%と良好であった。The angle of repose of the obtained granular material was 44°, there was no seepage of oil or fat, and the hardness of the granular material was good at 91.7%.
また、該粉末油脂を水に入れると、油脂が速やかに分離
した。Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
以下の実施例2〜実施例14においても同様の製造方法
にて行う。The following manufacturing methods are also used in Examples 2 to 14.
実施例2
ゲファルナート 35重量部軽質無水ケ
イ酸 IO重量部ポリビニルピロリドン(
K−90) 2重量部パインデンクス[F]# 1
(DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は46゜で、油
脂の浸み出しは全くなく、粉粒体の固さも89.7%と
良好であった。また、該粉末油脂を水に入れると、油脂
が速やかに分離した。Example 2 Gefarnate 35 parts by weight Light silicic anhydride IO Parts by weight Polyvinylpyrrolidone (
K-90) 2 parts by weight Pine Denks [F] #1
(DE・8) 53 parts by weight glycerin
The angle of repose of the granular material obtained at 3 parts by weight was 46°, there was no seepage of oil or fat, and the hardness of the granular material was good at 89.7%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例3
リノール酸 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデノクス■# 1 (D
E・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は42゜で、油脂の浸
み出しは全くなく、粉粒体の固さも84.7%と良好で
あった。また、該粉末油脂を水に入れると、油脂が速や
かに分離した。Example 3 Linoleic acid 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pine Denox ■#1 (D
E.8) 53 parts by weight glycerin
The angle of repose of the powder obtained at 3 parts by weight was 42°, there was no seepage of oil and fat, and the hardness of the powder was good at 84.7%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例4
リノレン酸 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス[F]# 1
(DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は43゜で、油脂
の浸み出しは全くなく、粉粒体の固さも90.7%と良
好であった。また、該粉末油脂を水に入れると、油脂が
速やかに分離した。Example 4 Linolenic acid 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Paindex [F] #1
(DE・8) 53 parts by weight glycerin
The angle of repose of the powder obtained at 3 parts by weight was 43°, there was no seepage of oil and fat, and the hardness of the powder was good at 90.7%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例5
アラキドン酸 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス[F]# 1
(DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は43゜で、油脂
の浸み出しは全くなく、粉粒体の固さも85.1%と良
好であった。また、該粉末油脂を水に入れると、油脂が
速やかに分離した。Example 5 Arachidonic acid 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Paindex [F] #1
(DE・8) 53 parts by weight glycerin
The angle of repose of the powder obtained in 3 parts by weight was 43°, there was no oozing of oil and fat, and the hardness of the powder was good at 85.1%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例6
ドコサヘキサエン酸 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス[F]# 1
(DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は40’で、油脂
の浸み出しは全くなく、粉粒体の固さも83.9%と良
好であった。また、該粉末油脂を水に入れると、油脂が
速やかに分離した。Example 6 Docosahexaenoic acid 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Paindex [F] #1
(DE・8) 53 parts by weight glycerin
The angle of repose of the powder obtained at 3 parts by weight was 40', there was no seepage of oil and fat, and the hardness of the powder was good at 83.9%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例7
ハッカ油 35重量部軽質無水ケイ
酸 10重量部ポリビニルビロリドン(K
−90) 2重量部パインデノクス■# l (D
H・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は46゜で、油脂の浸
み出しは全くなく、粉粒体の固さも89.0%と良好で
あった。また、該粉末油脂を水に入れると、油脂が速や
かに分離した。Example 7 Peppermint oil 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pinedenox■#l (D
H・8) 53 parts by weight glycerin
The angle of repose of the powder obtained at 3 parts by weight was 46°, there was no seepage of oil and fat, and the hardness of the powder was good at 89.0%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例8
ビタミン八油 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部ビタミンC
53重量部グリセリン 3重量部
得られた粉粒体の安息角は45゜で、油脂の浸み出しは
全くなく、粉粒体の固さも86.4%と良好であった。Example 8 Vitamin 8 oil 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Vitamin C
53 parts by weight Glycerin 3 parts by weight The angle of repose of the obtained powder was 45°, there was no oozing of oil and fat, and the hardness of the powder was good at 86.4%.
また、該粉末油脂を水に入れると、油脂が速やかに分離
した。Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例9
ソイステロール 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス■# 1 (D
E=87 5 3重量部グリセリン
3重量部得られた粉粒体の安息角は46゜で、油脂
の浸み出しは全くなく、粉粒体の固さも87.2%と良
好であった。また、該粉末油脂を水に入れると、油脂が
速やかに分離した。Example 9 Soysterol 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pine Index ■#1 (D
E=87 5 3 parts by weight glycerin
The angle of repose of the powder obtained in 3 parts by weight was 46°, there was no oozing of oil and fat, and the hardness of the powder was good at 87.2%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例10
EPA 3 5重量部軽質無水
ケイ酸 10重量部ポリビニルピロリドン
(K−90) 2 m m 部パインデックス■#
1 (DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は44゜で
、油脂の浸み出しは全くなく、粉粒体の固さも84.9
%と良好であった。また、該粉末油脂を水に入れると、
油脂が速やかに分離した。Example 10 EPA 3 5 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K-90) 2 mm parts Pa index ■#
1 (DE・8) 53 parts by weight glycerin
The angle of repose of the powder and granules obtained in 3 parts by weight was 44°, there was no seepage of oil and fat, and the hardness of the powder and granules was 84.9.
%, which was good. Also, when the powdered oil is added to water,
The fat and oil separated quickly.
実施例11
トリベノシド 35重量部軽質無水ケイ
酸 io重量部ポリビニルピロリドン(K
−90) 2重量部パインデンクス■# 1 (D
E・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は46゜で、油脂の浸
み出しは全くなく、粉粒体の固さも82.4%と良好で
あった。また、該粉末油脂を水に入れると、油脂が速や
かに分離した。Example 11 Tribenoside 35 parts by weight Light silicic anhydride io Parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pine Denks ■#1 (D
E.8) 53 parts by weight glycerin
The angle of repose of the granular material obtained at 3 parts by weight was 46°, there was no seepage of oil or fat, and the hardness of the granular material was good at 82.4%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例l2
オルノブロスチル 35重量部軽質無水ケイ
酸 IO重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス[F]# l
([lE=8) 5 3重量部グリセリン
3重量部得られた粉粒体の安息角は40゜で
、油脂の澄み出しは全くなく、粉粒体の固さも80.1
%と良好であった。また、該粉末油脂を水に入れると、
油脂が速やかに分離した。Example 12 Ornobrostil 35 parts by weight Light silicic anhydride IO Parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pine index [F] #l
([lE=8) 5 3 parts by weight glycerin
The angle of repose of the powder and granules obtained in 3 parts by weight was 40°, there was no clarification of fat and oil, and the hardness of the powder and granules was 80.1.
%, which was good. Also, when the powdered oil is added to water,
The fat and oil separated quickly.
実施例l3
ドコサヘキサエン酸 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス■# 1 (D
E・8) 53重量部グリセリン
3重量部得られた籾粒体の安息角は43゜で、油脂の浸
み出しは全くなく、粉粒体の固さも88.9%と良好で
あった。また、該粉末油脂を水に入れると、油脂が速や
かに分離した。Example 13 Docosahexaenoic acid 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pine Index ■#1 (D
E.8) 53 parts by weight glycerin
The angle of repose of the rice granules obtained at 3 parts by weight was 43°, there was no oozing of oil and fat, and the hardness of the granules was good at 88.9%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例14
クロフィブラート 35重量部軽質無水ケイ
酸 10重量部ポリビニルピロリドン(K
−90) 2重量部パインデックス[F]# l
(DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は46゜で、油脂
の浸み出しは全くな<、籾粒体の固さも89.5%と良
好であった。また、該粉末油脂を水に入れると、油脂が
速やかに分離した。Example 14 Clofibrate 35 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K
-90) 2 parts by weight Pine index [F] #l
(DE・8) 53 parts by weight glycerin
The angle of repose of the granules obtained in 3 parts by weight was 46°, there was no oozing of oil and fat, and the hardness of the rice granules was as good as 89.5%. Further, when the powdered oil and fat were added to water, the oil and fat were quickly separated.
実施例15
N4−バルミトイルーβ−D−アラビノフラノシルシト
シン 1 重mmゴマ油 3
5重量部軽質無水ケイ酸 10重量部ポリ
ビニルピロリドン(K−90) 2重量部パインデ
ックス■# 1 (DE=8) 5 3重量部グリセ
リン 3重量部製造方法
7重量部のN4−バルミトイB−β−D−アラビノフラ
ノシルシトシンと 35重量部のゴマ油を分散懸濁化し
た後、10重量部の軽質無水ケイ酸と2重量部のポリビ
ニルピロリドン(K−90)および53重量部のパイン
デ・ノクス[F]#1を加え十分に混練後、さらに、3
重量部のグリセリンを添加し、均一になるように攪拌を
行い造粒工程後、60″05分間加熱することにより粉
粒体を得た。得られた粉粒体の安息角は43゜で、油脂
の浸み出しは全くなく、粉粒体の固さも87.7%と良
好であった。Example 15 N4-valmitoyl-β-D-arabinofuranosylcytosine 1 heavy mm sesame oil 3
5 parts by weight Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K-90) 2 parts by weight Pine Index #1 (DE=8) 5 3 parts by weight Glycerin 3 parts by weight Manufacturing method 7 parts by weight N4-Valmitoy B-β After dispersing and suspending -D-arabinofuranosylcytosine and 35 parts by weight of sesame oil, 10 parts by weight of light silicic anhydride, 2 parts by weight of polyvinylpyrrolidone (K-90) and 53 parts by weight of pinde nox. [F] Add #1 and mix thoroughly, then add 3
Parts by weight of glycerin were added, stirred to make it uniform, and after the granulation process, a powder was obtained by heating for 60"05 minutes.The angle of repose of the obtained powder was 43 degrees, There was no seepage of oil or fat, and the hardness of the powder was good at 87.7%.
以下の実施例l6〜実施例l9においても同様の製造方
法にて行う。Similar manufacturing methods were used in Examples 16 to 19 below.
実施例l6
ニフェジピン 2.8重量部大豆油
35重量部軽質無水ケイ酸
10重量部ポリビニルピロリドン(K−90)
2重量部パインデンクス[F]# 1 (DE・8)
53重量部グリセリン 3重量部
得られた粉粒体の安息角は43゜で、油脂の浸み出しは
全くなく、粉粒体の固さも88.1%と良好であった。Example 16 Nifedipine 2.8 parts by weight Soybean oil
35 parts by weight light silicic anhydride
10 parts by weight polyvinylpyrrolidone (K-90)
2 parts by weight Pine Denks [F] #1 (DE・8)
53 parts by weight Glycerin 3 parts by weight The angle of repose of the obtained powder was 43°, there was no oozing of oil and fat, and the hardness of the powder was good at 88.1%.
実施例17
ビタミンK2 15重量部大豆油
35重量部軽質無水ケイ酸
10重量部ポリビニルピロリドン(K−90)
2重量部ビタξンC 53重量
部グリセリン 3重量部得られた粉
粒体の安息角は41゜で、油脂の浸み出しは全くなく、
粉粒体の固さも91.3%と良好であった。Example 17 Vitamin K2 15 parts by weight Soybean oil
35 parts by weight light silicic anhydride
10 parts by weight polyvinylpyrrolidone (K-90)
2 parts by weight Vitamin ξ C 53 parts by weight Glycerin 3 parts by weight The angle of repose of the obtained powder was 41°, and there was no seepage of oil or fat.
The hardness of the powder was also good at 91.3%.
実施例l8
ビタミンD2 15重量部大豆油
35重量部軽質無水ケイ酸
10重量部ポリビニルビロリドン(K−90)
’2重量部ビタミンC 53重量
部グリセリン 3重量部得られた粉
粒体の安息角は46゜で、油脂の浸み出しは全くなく、
粉粒体の固さも88.1%と良好であった。Example 18 Vitamin D2 15 parts by weight soybean oil
35 parts by weight light silicic anhydride
10 parts by weight polyvinylpyrrolidone (K-90)
'2 parts by weight Vitamin C 53 parts by weight Glycerin 3 parts by weight The angle of repose of the obtained powder was 46°, and there was no seepage of oil or fat.
The hardness of the powder was also good at 88.1%.
実施例l9
アンホテリシンー8 7重量部テ才キシゴー
ル 酸ナトリウム 5. 6
重量部大豆油 35重量部軽質無
水ケイ酸 10重量部ポリビニルビロリド
ン(K−90) 2重量部パインデックス[F]#
1 (DE・8) 53重量部グリセリン
3重量部得られた粉粒体の安息角は46゜で
、油脂の浸み出しは全くなく、粉粒体の固さも86.7
%と良好であった。Example 19 Amphotericin-8 7 parts by weight Sodium dioxygol 5. 6
Parts by weight Soybean oil 35 parts Light silicic anhydride 10 parts by weight Polyvinylpyrrolidone (K-90) 2 parts by weight Pine index [F]#
1 (DE・8) 53 parts by weight glycerin
The angle of repose of the powder and granules obtained in 3 parts by weight was 46°, there was no seepage of oil and fat, and the hardness of the powder and granules was 86.7.
%, which was good.
(ほか■名)(other names)
Claims (1)
基剤、0.1〜10重量%のポリオール、1〜20重量
%の油脂吸収基剤および0.1〜15重量%の結合剤か
らなる油脂含有組成物。1-70% by weight of fats and oils, 30-90% by weight of base for fat and oil inclusion, 0.1-10% by weight of polyol, 1-20% by weight of fat-absorbing base and 0.1-15% by weight of binding. An oil- and fat-containing composition consisting of an agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29951289A JPH03161448A (en) | 1989-11-20 | 1989-11-20 | Composition containing oil and fat |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29951289A JPH03161448A (en) | 1989-11-20 | 1989-11-20 | Composition containing oil and fat |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH03161448A true JPH03161448A (en) | 1991-07-11 |
Family
ID=17873547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29951289A Pending JPH03161448A (en) | 1989-11-20 | 1989-11-20 | Composition containing oil and fat |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH03161448A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0841010A1 (en) * | 1996-11-06 | 1998-05-13 | F. Hoffmann-La Roche Ag | Stable compositions dispersible in cold water |
WO2001047560A3 (en) * | 1999-12-23 | 2002-01-17 | Aventis Animal Nutrition Sa | Particulate vitamin composition |
WO2002068056A3 (en) * | 2001-02-23 | 2003-05-15 | Ks Biomedix Holdings Plc | Combination comprising a 1,4-dioxonaphathalene compound and ribenoside |
WO2007022891A1 (en) * | 2005-08-23 | 2007-03-01 | Cognis Ip Management Gmbh | Powdery sterol formulations comprising colloid-forming agents |
KR100765005B1 (en) * | 1998-05-26 | 2007-10-09 | 에자이 가부시키가이샤 | Powder Containing Fat-Soluble Drug |
CN105613789A (en) * | 2016-03-14 | 2016-06-01 | 广州金酮医疗科技有限公司 | High-fat and high-dietary-fiber composite animal and plant powdered oil and preparation method and application thereof |
-
1989
- 1989-11-20 JP JP29951289A patent/JPH03161448A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0841010A1 (en) * | 1996-11-06 | 1998-05-13 | F. Hoffmann-La Roche Ag | Stable compositions dispersible in cold water |
KR100765005B1 (en) * | 1998-05-26 | 2007-10-09 | 에자이 가부시키가이샤 | Powder Containing Fat-Soluble Drug |
WO2001047560A3 (en) * | 1999-12-23 | 2002-01-17 | Aventis Animal Nutrition Sa | Particulate vitamin composition |
WO2002068056A3 (en) * | 2001-02-23 | 2003-05-15 | Ks Biomedix Holdings Plc | Combination comprising a 1,4-dioxonaphathalene compound and ribenoside |
WO2007022891A1 (en) * | 2005-08-23 | 2007-03-01 | Cognis Ip Management Gmbh | Powdery sterol formulations comprising colloid-forming agents |
CN105613789A (en) * | 2016-03-14 | 2016-06-01 | 广州金酮医疗科技有限公司 | High-fat and high-dietary-fiber composite animal and plant powdered oil and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3965256A (en) | Slow release pharmaceutical compositions | |
JP2948317B2 (en) | Chewable drug administration composition | |
US4235870A (en) | Slow release pharmaceutical compositions | |
EP0377658B1 (en) | A free-flowing granular composition containing ibuprofen and a method for its preparation | |
DE4225730C2 (en) | Process for the preparation of solid dosage forms with protracted 2-stage release | |
KR940002659B1 (en) | Process for therapeutic compositions | |
WO1988006457A1 (en) | Medicinal composition containing albumin as carrier and process for its preparation | |
KR101381263B1 (en) | Process for the manufacture of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate | |
AU2006240551A1 (en) | Pharmaceutical dosage forms comprising a lipid phase | |
JPH0129764B2 (en) | ||
JPH0474339B2 (en) | ||
JPS6140204B2 (en) | ||
SG184950A1 (en) | Fexofenadine-based composition and preparation process therefor | |
JP2001501218A (en) | Method for producing a pharmaceutical composition comprising a matrix with modified release of active ingredient | |
JP2004500193A (en) | Continuous production method of granules | |
JPS6230965B2 (en) | ||
WO2010095494A1 (en) | Granules containing poorly soluble substance, tablet, and method for solubilizing poorly soluble substance | |
JPH03161448A (en) | Composition containing oil and fat | |
US4670251A (en) | Microcrystalline tableting excipient derived from whey | |
JP5249568B2 (en) | Molding powder, compression molding composition using the same, and method for producing molding powder | |
JPH04505418A (en) | Encapsulation of active substances with starch | |
JP4532903B2 (en) | Fine particle composition | |
WO2008111871A1 (en) | Peroral memantine-based medicinal preparation and a method for the production thereof | |
CA2516448A1 (en) | Method for preparation of an agglomerate using melt agglomeration | |
JPS63243034A (en) | Solid agent containing low-melting substance |